stable-labeled [^13 C 2 ]omapatrilat after oral administration to rats, dogs, and humans.
Drug Metab Dispos 2003;31:67–75.
Iyer RA, Mitroka J, Malhotra B, Bonacorsi SJ, Waller SC, Rinehart JK, Roongta VA,
Kripalani K. Metabolism of [^14 C]omapatrilat, a sulfhydryl-containing vasopeptidase
inhibitor in humans. Drug Metab Dispos 2001;29:60–69.
Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Effects of gemfibrozil,
itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin
Pharmacol Ther 2005;77:404–414.
Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and
development. Med Res Rev 2001;21:397–411.
Lilja JJ, Backman JT, Neuvonen PJ. Effect of gemfibrozil on the pharmacokinetics and
pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol
2005;59:433–439.
Lu AY, Wang RW, Lin JH. Cytochrome P450in vitroreaction phenotyping: a
re-evaluation of approaches used for P450 isoform identification. Drug Metab
Dispos 2003;31:345–350.
Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S,
Gilbert D, Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson
A, Christ D, Selling B, LeCluyse E, Gan LS. CYP3A4 induction by drugs:
correlation between a pregnane X receptor reporter gene assay and CYP3A4
expression in human hepatocytes. Drug Metab Dispos 2002;30:795–804.
Luo G, Guenthner T, Gan LS, Humphreys WG. CYP3A4 induction by xenobiotics:
biochemistry, experimental methods and impact on drug discovery and development.
Curr Drug Metab 2004;5:483–505.
Marathe PH, Shyu WC, Humphreys WG. The use of radiolabeled compounds for
ADME studies in discovery and exploratory development. Curr Pharm Des
2004;10:2991–3008.
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and
disposition of resveratrol in rats: extent of absorption, glucuronidation, and
enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp
Ther 2002;302:369–373.
Martignoni M, Monshouwer M, de Kanter R, Pezzetta D, Moscone A, Grossi P. Phase I
and phase II metabolic activities are retained in liver slices from mouse, rat, dog,
monkey and human after cryopreservation. Toxicol In Vitro 2004;18:121–128.
McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and
cryopreserved hepatocytes asin vitrodrug metabolism tools for the prediction of
metabolic clearance. Drug Metab Dispos 2004;32:1247–1253.
Mei Q, Tang C, Assang C, Lin Y, Slaughter D, Rodrigues AD, Baillie TA, Rushmore TH,
Shou M. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in
assessment of human drug metabolism. J Pharmacol Exp Ther 1999;291:749–759.
Mutlib AE, Chen H, Nemeth GA, Markwalder JA, Seitz SP, Gan LS, Christ DD.
Identification and characterization of efavirenz metabolites by liquid chromato-
graphy/mass spectrometry and high field NMR: species differences in the metabolism
of efavirenz. Drug Metab Dispos 1999;27:1319–1333.
Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik
B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT. The
REFERENCES 283